Travere Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
All right, I think we are live. Good afternoon, everyone. Thanks for joining us on the second day of our fifth annual Guggenheim Genomic Medicines and Rare Disease Day. I'm Vamil Divan, one of the senior analyst here at Guggenheim. Joining -- Areseniy is also on the line from the Guggenheim side. And we got the full team here from the Travere Therapeutics side for our next session.
Thanks so much to all of you for joining us. We have Eric Dube, who is the President and CEO. We have Chris Cline, the CFO; and Peter Heerma, the CCO, along with Naomi Eichenbaum from Investor Relations.
And obviously, a lot to get to. So I'm just going to jump right in. But before I do that, for those of you listening in, if you have any questions that you want me to ask, please feel free to e-mail me at [email protected] and I'll work them into the conversation. But I thought we could get started.
We obviously, this weekend, just had some additional data released at WCN. So maybe if you guys just want to share, I guess I'll turn this to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |